Mesoblast (MESO) Stock Price, News & Analysis

Company Overview

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease. In addition, Mesoblast’s lead investigational candidate, remestemcel-L, is in late-stage development in the United States for the treatment of pediatric patients with steroid-refractory acute graft-versus-host disease. Beyond these programs, Mesoblast maintains a diversified pipeline targeting heart failure, low back pain due to disc degeneration, and other immune-driven disorders, with multiple Phase 2 and Phase 3 trials underway.

Headquartered in Melbourne, Australia, with a major corporate office in New York City, Mesoblast operates research and manufacturing facilities across North America, Europe, and the Asia–Pacific region. The company collaborates with strategic partners and regulatory authorities worldwide to advance its programs, ensuring broad geographic reach in both clinical development and commercial distribution.

Under the leadership of founder and CEO Dr. Silviu Itescu, Mesoblast emphasizes rigorous clinical research, regulatory compliance, and scalable manufacturing processes. The company’s management team combines expertise in cell biology, clinical development, and partnership licensing to support its mission of bringing transformative therapies to patients with high unmet medical needs.

Key Stats

• Today's Range: $17.08 to $17.65
• 50-Day Range: $12.88 to $18.41
• 52-Week Range: $7.09 to $22.00
• Volume: 299,445 shs
• Average Volume: 276,184 shs
• Market Capitalization: $2.22 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.00
• Consensus Rating: Moderate Buy

Mesoblast Stock Analysis - MarketRank™

Mesoblast scored higher than 42% of companies evaluated by MarketBeat, and ranked 669th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Mesoblast has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Mesoblast has a consensus price target of $24.00, representing about 38.6% upside from its current price of $17.32.

Amount of Analyst Coverage

Mesoblast has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Mesoblast are expected to grow in the coming year, from ($0.70) to ($0.32) per share.

Price to Book Value per Share Ratio

Mesoblast has a P/B Ratio of 3.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.01% of the outstanding shares of Mesoblast have been sold short.

Short Interest Ratio / Days to Cover

Mesoblast has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.

Change versus previous month

Short interest in Mesoblast has recently increased by 6.20%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mesoblast does not currently pay a dividend.

Dividend Growth

Mesoblast does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.01% of the outstanding shares of Mesoblast have been sold short.

Short Interest Ratio / Days to Cover

Mesoblast has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.

Change versus previous month

Short interest in Mesoblast has recently increased by 6.20%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.58

News Sentiment

Mesoblast has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Mesoblast this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for MESO on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Mesoblast to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mesoblast insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.80% of the stock of Mesoblast is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 1.43% of the stock of Mesoblast is held by institutions.

MESO Stock Analysis - Frequently Asked Questions

How have MESO shares performed this year?

Mesoblast's stock was trading at $19.80 at the start of the year. Since then, MESO shares have decreased by 12.5% and is now trading at $17.32.

How were Mesoblast's earnings last quarter?

Mesoblast Limited (NASDAQ:MESO) posted its earnings results on Wednesday, August, 30th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.06. The company earned $2.14 million during the quarter, compared to the consensus estimate of $2 million.
Read the conference call transcript.

When did Mesoblast's stock split?

Mesoblast shares reverse split on the morning of Friday, January 5th 2024.The 1-2 reverse split was announced on Friday, January 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 50 shares after the split.

When did Mesoblast IPO?

Mesoblast (MESO) raised $69 million in an initial public offering on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

How do I buy shares of Mesoblast?

Shares of MESO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Mesoblast own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mesoblast investors own include NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Meta Platforms (META), CRISPR Therapeutics (CRSP) and Corbus Pharmaceuticals (CRBP).

Company Calendar

• Last Earnings: 8/30/2023
• Today: 10/06/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MESO
• Previous Symbol: OTCMKTS:MBLTY
• CIK: 1345099
• Web: www.mesoblast.com
• Phone: (139) 639-6036
• Fax: 61-3-9639-6030
• Employees: 80
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Mesoblast: $24.00
• High Price Target: $24.00
• Low Price Target: $24.00
• Potential Upside/Downside: +38.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.11
• Current Ratio: 1.99
• Quick Ratio: 1.77

Sales & Book Value

• Annual Sales: $17.20 million
• Price / Sales: 128.89
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.67 per share
• Price / Book: 3.71

Miscellaneous

• Outstanding Shares: 128,000,000
• Free Float: 103,934,000
• Market Cap: $2.22 billion
• Optionable: Optionable
• Beta: 2.30